full list rate price target
earn chang report pleas see
tabl page
import datapoint track
broadli believ posit end market trend creat good setup life
scienc tool diagnost coverag believ organ trend
import datapoint track alway tracker survey industri expert
event management meet suggest posit trend continu quarter
highest convict thesi nation lab labcorp
quest ow highlight near-term volum favor quest
upgrad favor risk/reward new payor paradigm upgrad
ow benefit solid underli util retail expans
 complet addit lab favor comp y/i q/q
time favor weather beyond quarter lab
number catalyst potenti share gain hospit region
lab advanc nation payor contract open well potenti
updat lab benefit design chang view valuat
compel sub-seg coverag trade price-to-earnings
life scienc tool concern relat global trade tool
ytd vs macro datapoint still appear support
industri end market beyond academ healthcar biopharma end market
appear align healthi fund cautiou around fx given usd
strengthen sinc late april point think earn impact still
off-set better organ growth expens management capit deploy
ytd almost data point track biopharma end market
look posit start surpris rel under-perform
iqvia ytd despit solid new award continu share buy-back
quarter also favor labcorp health strategi categori
diagnost continu favor kit manufactur
ow dx strong start ytd trade
premium tool brethren ev/sal attribut solid fundament
market demand growth consolid activ execut
believ earn reset last quarter serv baselin
growth believ favor end market exposur person
medicin recur revenu still underappreci anoth
strong quarter cardiac immunoassay trend would highlight execut synergi
triage/bnp deal opportun futur deal well
action adjust model fx deploy
pleas see end market tracker survey biopharma end market
biopharma tracker healthi end market read
industri end market barclay tool industri tracker june
pmi expansionari amidst increas focu end market dx/lab end market
lab april employ trend review ob/gyn
survey say volum solid surgic competit focu
aesthet survey say healthi demand need execut
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
link barclay end market tracker survey
link industri expert event replay
link takeaway industri confer
action adjust fx announc cap deploy
stock price perform valuat
broadli believ posit end market trend creat good setup life scienc
tool diagnost coverag believ organ trend import
datapoint track alway tracker survey industri expert event management
meet suggest posit trend continu quarter
highest convict thesi nation lab labcorp top pick
quest ow highlight near-term volum favor quest
upgrad favor risk/reward new payor paradigm upgrad
ow benefit solid underli util retail expans
complet addit lab favor comp y/i q/q
time favor weather beyond quarter lab number
catalyst potenti share gain hospit region lab
advanc nation payor contract open well potenti updat lab
benefit design chang view valuat compel
sub-seg coverag trade price-to-earnings
life scienc tool concern relat global trade tool
ytd vs macro datapoint still appear support industri
end market beyond academ healthcar biopharma end market align
healthi fund cautiou around fx given usd strengthen sinc late
april point think earn impact still off-set better organ
growth expens management capit deploy ytd almost
data point track biopharma end market look posit start
surpris rel under-perform iqvia ytd despit solid new
award continu share buy-back quarter also favor labcorp
strategi categori
diagnost continu favor kit manufactur
ow dx strong start ytd trade
premium tool brethren ev/sal attribut solid fundament market
demand growth consolid activ execut
believ earn reset last quarter serv baselin growth
believ favor end market exposur person medicin recur
revenu still underappreci anoth strong quarter cardiac
immunoassay trend would highlight execut synergi triage/bnp deal
opportun futur deal well
link barclay end market tracker survey
biopharma end market biopharma tracker healthi end market
read
industri end market barclay tool industri tracker june
pmi expansionari amidst increas focu end market
ob/gyn survey say volum solid surgic competit focu
myriad genet genesight survey say psych like get paid
proprietari novaseq survey say elast upgrad
aesthet survey say healthi demand need execut
link industri expert event replay
oncologist view dx post-asco tool time expert call
ob/gyn perspect dx gyn surgic medic aesthet tool
time expert call
psychiatrist view myriad genesight tool time expert call
industri updat novaseq survey tool time expert call
lab diagnost industri updat tool time expert call
medic aesthet industri updat tool time expert call
bioproduct industri updat post-interphex tool time expert
lab director takeaway dx platform oper environ
lab director takeaway pama impact lab dx
link takeaway industri confer
asm tool kit volume issu takeaway asm
ghdx tailorx show valu intermedi risk patient fulli
valu stock
war colleg tool kit volume issu lab battl line drawn war
takeaway analyst session pama mdx
takeaway lab director dinner
corpor workshop takeaway focu
takeaway aacc lab director dinner
action adjust fx announc cap deploy
make adjust life scienc tool model relat fx specif
agil thermo fisher
includ full model compani specif section
number global currenc began weaken vs us dollar late april compani
report earn import currenc coverag
euro chines yuan natur hedg global manufactur
sale versu usd currenc weaken respect ytd
though move much pronounc sinc april japanes yen held
best import sinc chang currenc meaning earn
impact coverag gener none life scienc tool meaning
manufactur presenc region help off-set fx chang weaken uk
pound posit uniqu cost exposur region
estim water gener revenu uk though doubl
exposur cost base said continu weaken indian rupe also
notabl impact given lc exposur gener manufactur
region ytd rupe weaken vs us dollar
point think coverag enough offset manag expens deploy
capit off-set ep impact though moder temper
expect sever compani addit thermo fisher emb
announc tuck-in acquisit gatan forecast expect close year
end expect accret least off-set modest headwind fx
agil emb million announc buy-back may off-set fx
ytd chang notabl currenc vs usd
estim chang life scienc tool
compani document barclay research note iqvia health syneo health repres ep figur adjust inc stock comp
stock price perform valuat
stock perform present price
enterpris valu life scienc tool compani trade near twelv
month ntm ebitda estim compar five year averag ntm
ebitda ten year averag ntm ebitda past five year group
broadli trade within rang forward ebitda
enterpris valu diagnost compani trade near twelv month
ntm ebitda estim compar five-year averag ntm ebitda
ten-year averag ntm ebitda past five year group broadli
trade within rang forward ebitda
enterpris valu cro compani trade near twelv month ntm
ebitda estim compar five-year averag ntm ebitda ten-
year averag ntm ebitda past five year group broadli trade
within rang forward ebitda
enterpris valu lab compani trade near twelv month ntm
ebitda estim compar five-year averag ntm ebitda ten-
year averag ntm ebitda past five year group broadli trade
within rang forward ebitda
recent thought
see report
consist strategi out-
think setup agil head earn much favor
last quarter sever reason focus compani ep
guidanc think agil could posit rais fundament think
favor underli end market condit bode well agil exposur biopharma
rev chemic energi end market addit one time chang
net posit agil vs net neg last quarter
specif agil previous note icp-m order delay last quarter
could pull quarter contrast agil
miss time sale also face unfavor comp
time chines new year addit agil opportunist repurchas
million share may given stock weak quarterli print final agil
close aati acquisit million leverag agil commerci
reach addit earn also announc ultra scientif young
acquisit prozym acquisit close yet reiter overweight
rate believ agil premium top line growth deserv premium valuat
tool peer current trade discount vs tool peer
ep contribut capit deploy
note repurchas accret assum share outstand end
total benefit repurchas share repurchas midhighshar priceaati close close aati share repurchas contributionrevenu million share margin repurchaserepurchas barclay life scienc tool diagnost
estestestestassumpt detailslif scienc appli marketslsag y/i growth ex-nmrdgg y/i y/i revenu market trackerpharma total growth y/i total growth y/i total growth y/i total growth y/i total growth y/i total growth y/i growth y/i barclay life scienc tool diagnost
estestestestestestestestestestincom statement growth growth growth growth growth growth growth ex-fx growth product product product revenu inc servic servic gross margin inc less stock-bas growth growth y/i less stock-bas sg ex-comp growth growth y/i stock-bas stock sg growth ebitda growth net oper incom ebit growth invest interest debt interest incom expens incom pre-tax growth incom tax net net growth averag share basic net incom per share adj basic dilut growth barclay life scienc tool diagnost
agil statement flow
estestestestestestestestesteststat flow oper activ net reconcil net incom cffodepreci amort interest rate swap tax benefit share-bas obsolet inventori relat restructur asset impair gain sale gain loss sale asset doubt non-cash expens asset liabil account compens tax tax rate swap asset capit cash provid oper growth adj net flow invest activ capit growth sale properti plant leas acquir equiti method restrict cash cash equival equiti method sale cash use invest flow financ activ issuanc common stock employe stock growth non-control tax benefit share-bas senior issuanc short-term revolv credit revolv credit senior cash use financ exchang rate decreas cash cash cash equival begin cash equival end growth net barclay life scienc tool diagnost
estestestestestestbal sheet asset cash restrict cash cash receiv current current plant equip intang asset restrict cash cash equitycurr liabil account compens accru current post-retir long-term stockhold liabil barclay life scienc tool diagnost
overweight agil built strong track
record reput oper perform
develop divers portfolio busi
across instrument diagnost favor
agil exposur growth biopharma
rev new product cycl ga chromatographi
opportun repatri drive upsid
improv growth chemic energi end
market due stabil trend gc product
cycl could lead better growth capit alloc
also remain opportun upsid case
reflect upsid ebitda billion
agil exposur econom activ end
market could impact growth downsid
case reflect downsid ebitda
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas see ndr takeaway
management
optim fund new
pleas see asm
takeaway
takeaway asm
bruker quarterli earn alway bit black box given capit natur
compani sale focu sign compani growth driver sale
continu show healthi trend remain revenu support
overal growth easiest metric track after-market revenu sale
disclos quarterli basi file new product nich market
rev repres good opportun compani addit time
posit updat quarter new product includ
bologna workflow clinic mass spec platform maldi-tof well new launch
asm tims-tof mr-m addit announc two addit uhf
order academ center uk expect continu drive margin
expans time per year though quarterli progress difficult
pars convers commentari around china cautiou
market product begin moder addit think outstand
sec subpoena investig compani overhand valuat
much compani add point time resolut
reiter equal weight rate
estestestestestassumpt segmenttot bsi y/i best y/i y/i contributionbsi organ organ organ organ organ revenu store acquisiton currenc y/i total y/i total y/i total y/i total barclay life scienc tool diagnost
estestestestestestestincom statement growth growth growth growth growth growth y/i growth product product product revenu inc servic servic gross gross margin inc growth administr growth stock base sg stock charg ebitda growth acquir intang oper incom ebit growth expens debt incom expens pre-tax pre-tax growth incom tax net net growth dilut adjust ep continu opsbas adj adj net barclay life scienc tool diagnost
statement
estestestestestestest statement activ net defer financ inventori compens incom gain dispos product non-cash expens work capitalaccount payabl accur tax payabl chang oper asset chang asset oper growth adj net activitiescapit growth short-term short-term paid acquisit net dispos product sale cash use invest activ repay revolv line revolv line note purchas debt defer financ issuanc common conting common restrict payment non-control tax benefit relat stock connect paid per cash financ exchang rate changein cash equival begin equival end growth adj net barclay life scienc tool diagnost
sheet cash short-term restrict account receiv current current properti plant equip net long-term total stockohold equityshort-term portion long-term account custom current total current long-term long-term total sharehold equiti interest consolid total sharehold liabil sharehold barclay life scienc tool diagnost
equal weight view thesi
balanc biggest turnaround
stori life scienc tool coverag
begin see earli sign better sale
manag system drive higher earn
compani said revenu visibl
weaken remain cautiou around
execut success
expect aid new manag system
support fund environ appli
ebitda multipl upsid ebitda
million yield upsid case
execut issu fund capit purchas
drive downsid ebitda forecast
case
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
read
favor fund across biopharma continu support underli growth
charl river highlight biopharma end market tracker smid biotech cash
hand remain time high actual increas start back
increas ipo activ categori market leader earli develop charl
river benefit trend post organ growth includ
discoveri safeti assess dsa segment expect growth momentum
continu forecast organ growth also forecast
ep repres growth y/i consist management guidanc low-to-mid teen
given backdrop focu quarter charl river oper
margin trajectori abil balanc invest growth meet
custom demand remind overal oper margin
y/i charl river cite margin declin primarili driven time issu fx
expect trend revers specif dsa oper margin lag studi
mix headwind anticip normal result oper margin
segment addit fx headwind margin dsa
compani natur hedg safeti assess busi canada
earli discoveri within manufactur soft holiday time
anticip revers said compani continu make invest
new biolog manufactur order off-set capac constraint busi
charl river pleas rm margin offset pressur declin
demand research model develop region headwind move forward
charl river oper margin improv segment
oper margin commentarydiscoveri safeti assess dsa -adjust oper margin headwind fx-studi mix headwind anticip normal like less tailwind rel model servic rm -adjust oper margin y/y-declin demand research model develop regions-w believ research model price positivemanufacturing-adjust oper margin demand due season holiday season-invest new biolog facil also improvementdiscoveri safeti assess dsa research model servic rm manufactur barclay life scienc tool diagnost
estestestestestassumpt growth y/i growth y/i organ growth model y/i y/i growth y/i organ growth gross ebit bpsdiscoveri safeti assess y/i growth y/i growth organ gross ebit bpsmanufactur support y/i growth y/i growth organ gross ebit bpscorporatereport unalloc unalloc total barclay life scienc tool diagnost
estestestestestincom statement y/i growth organ servic servic servic revenu inc servic revenu inc product product profit gross gross margin inc gross margin inc ex-comp sg compens stock comp margin margin annual bs annual bs debt incom pre-tax tax provis net averag sharesbas ep continu opsbas net margin net net margin barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight believ charl river
biggest beneficiari biopharma wave given
leadership posit earli stage drug
discoveri research said view thesi
balanc today valuat line
charl river continu benefit favor
safeti assess compani push price
expand capac drive upsid growth
upsid case repres upsid
ebitda million
charl river exposur earli stage biopharma
research make expos fund activ dis-
leverag safeti assess busi would lead
earn compress given fix cost
downsid case repres downsid
ebitda million
pleas see
intermedi risk patient
fulli valu stock barclay
pleas also see report
takeaway tool time
biggest area focu genom health oncotyp dx volum
commentari around june trend follow tailorx result present
remind result tailorx provid definit cutoff point women breast
cancer around benefit lack thereof chemotherapi interact
oncologist think like increment volum demand driven
tailorx said market matur penetr compani note
success tailorx one consider reflect upper end revenu
guidanc rang new product expect oncotyp begin contribut
revenu add growth intern would expect
result remain modest formal reimburs polici place
uk germani franc view valuat stretch
sale ebitda reiter underweight rate
estestestestestincom statement growth gross product revenu ex-comp margin inc comp margin net market admin debt stock base comp gross invest balanceoth incom expens debt outstandingadj pre-tax tax tax net net net incom loss per dilut comp per net dilut barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight genom oper
genom test best known oncotyp dx
platform substanti revenu come
invas breast cancer prognosi despit
matur product market continu
gener neg margin ahead new product
launch see near-term opportun
remedi situat
genom health success execut
opportun dci prostat cancer
intern market see upsid share
reflect upsid revenu
competit threat core product emerg
new product launch face greater headwind
adopt expect see downsid share
reflect downsid revenu
follow recent weak segment primari focu enter
gyn surgic novasur declin past quarter due introduct
minerva novasur remain standard care believ competitor exit
market creat void allow minerva gain share manag commentari
suggest action taken reinvigor salesforc gain traction think
recent favor rule patent litig minerva nice
boost moral well ultim believ solid quarter would help demonstr
gyn surgic segment return growth cynosur
view result rel de-risk short term manag reset
expect last quarter iron cynosur expect headwind growth
given strength intern oper prior year quarter model
declin segment return growth would like
manag provid updat insight compani progress get
salesforc product repres substanti area upsid potenti head
asid segment view remain busi segment
healthi came away recent manag meet convict around
durabl breast health growth profit also think diagnost
segment forecast could prove conserv given headwind face
sever winter weather flu season view valuat compel
price-to-earnings reiter overweight rate think execut key re-rat
pleas see ndr takeaway
align turnaround
execut
pleas see mammographi
updat
estestestestassumpt workday health total growth growth y/i total growth growth y/i ex-fx aesthet growth growth y/i surgic total growth growth y/i health total growth growth y/i ex-fx organ ex-sel barclay life scienc tool diagnost
estestestestincom statement y/i q/q y/i q/q y/i growth y/i growth y/i ex-fx organ ex-sel q/q product sale product product revenu inc servic gross gross margin inc y/i sale y/i stock comp sg y/i ebitda y/i oper incom ebit y/i invest expens outstand incom pre-tax y/i benefit incom tax net incom adj net y/i averag number share dilut y/i net barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ grow
stronger longer driven longer
mammographi tail mdx growth panther
myosur tuck-in new product launch
could drive modest upsid revenu
mdx gyn surgic busi continu
drive outsiz growth new product
launch add modestli growth upsid case
reflect upsid earn power
penetr rate us mammographi
busi slow faster expect downsid
case reflect downsid earn
power
icon focu earn compani abil convert continu
strong book acceler organ growth recent quarter new busi
trend strong icon recent gross award y/i
normal cancel level drove net book-to-bil expect organ growth
follow suit model acceler
acceler organ growth driven non-pfiz custom
post double-digit growth sinc larg trial cancel novemb
process revenu exposur decreas healthier level
compani expect maintain addit forecast mapi acquisit
contribut growth commentari around acquisit posit
continu see valu scale overal view icon one
effici oper cro industri believ valuat high-end peer
reflect optim thesi result pivot toward better growth
icon growth custom
estestestestestincom statement y/i y/i organ q/q revenu revenu revenu inc revenu inc profit gross margin gross margin gross margin inc gross margin inc expens ex-comp sg revenu sg inc comp sg inc growth compens stock comp sg stock stock comp growth y/i ebitda net net oper incom y/i ebit invest debt pre-tax y/i pre-tax tax tax interest net y/i net dilut basic adj adj y/i ebit ebit y/i dilut ep y/i net industri view neutral
equal weight icon success
transit nich european cro
becom intern top-tier cro recent result
show compani grow expect
headwind largest custom said
think compani need activ data
integr industri lead margin also impli
less room upsid
icon exhibit signific growth margin
expans improv custom diversif
would improv sentiment icon futur prospect
upsid case repres
upsid ebitda million
revenu concentr could continu
repres headwind overal growth similarli
industri cancel issu could continu begin
weigh icon growth margin downsid
case repres downsid
ebitda million
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
surpris rel under-perform iqvia ytd despit
solid new award continu share buy-back quarter focus
iqvia capit deploy compani continu aggress
sharehold friendli manner repurchas program recent iqvia
repurchas million share price part recent secondari offer
sell sharehold total deploy million repres roughli
compani market cap given compani substanti free cash flow
leverag roughli seem maintain
fundament look continu progress net book compani
integr strategi think net book bill new conserv
methodolog show iqvia abil win busi impress given size vs
peer tougher move needl reiter overweight rate note
compani trade essenti price-to-earnings cash ep
forecast ep growth next sever year
debt y/i growth barclay life scienc tool diagnost
estestestestestincom statement servic growth servic growth growth constant currenc organ good revenu inc revenu inc gross margin inc expens inc compens stock comp sg total sg y/i ebitda y/i ebitda y/i adj ebit y/i annual bs annual bs debt item expens pre-tax tax earn unconsolid interest/minor net net net y/i basic dilut y/i industri view neutral
overweight believ iqvia creat
best class platform cro industri believ
marri quintil cro platform im clinic
insight yield market share gain time
earn growth
believ iqvia valu proposit could yield
market share gain time coupl long
runway cost synergi upsid case
repres upsid adj ebitda
risk around integr recent growth
trend integr engag solut
busi could weigh near-term growth
downsid case repres downsid
adj ebitda billion
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas see
upgrad report
say elast
upgrad ow
number catalyst back beyond focus
compani consum growth think still earli
give meaning pull-through rang novaseq instrument survey
show custom much wider rang util prior
platform weight averag million said commentari around platform
growth give us sens pull-through trend bode well
year consum growth given multi-year adopt cycl instrument
beyond novaseq focus commentari relat popul sequenc initi
includ nih us clinic growth follow april coverag decis
panel consum test growth array kit sale servic revenu
geograph growth china rev believ mid-teen revenu growth
lead higher level earn growth time given higher margin aftermarket
revenu sale view current guidanc conserv context
acceler busi trend reiter overweight rate
illumina revenu growth product
segmentarray y/i miniseq instal y/i y/i stack y/i product y/i product product y/i servic y/i y/i barclay life scienc tool diagnost
estestestestestincom statement growth growth growth growth growth growth y/i growth product revenu ex product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth gener growth base sg stock base ebitda growth oper incom ebit growth invest debt expens pre-tax pre-tax growth incom tax non-control net net growth incom per basic ep inc non-cash growth interest net net growth growth net net barclay life scienc tool diagnost
overweight leader next
gener sequenc project
signific growth driven larg research studi
nascent opportun clinic diagnost
signific competit moat rel
competit given brand scale
growth forseeabl futur
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ep
growth ultim depend
nih well clinic reimburs
growth downsid case reflect
downsid ep
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
nation payor contract renew complet believ labcorp thesi
strong foot head area focu cro oper covanc
think continu momentum draw attent back compani enterpris
strategi msd organ growth ttm book bill strong
start year within diagnost expect organ volum trend remain strong
forecast volum growth driven final paml/mt sinai
partial quarter underli util approxim growth come
consum test think one-tim factor could posit
well movement easter/good friday lack sever weather
capit deploy remain opportun billion free cash flow expect
gener remaind overal labcorp top pick
believ valuat compel ebitda
millionsestestestestfisc year end dec growth organ growth dx metricslab growth acquir total access organ net new weather calendar underli ppa beacon organ lab rev medicar pama overal y/i organ growth metricsnet new busi y/i q/q y/i burn y/i y/i growth growth barclay life scienc tool diagnost
million except per share dataestestestestestfisc year end dec growth debt gross lab growth growth ex-fx organ growth increas gross cro net growth net margin net comp net net net intang loss equiti ebitda margin net net ebit margin net expens net debt pre-tax pre-tax incom tax average share average share ep ep increas net incom adj net margin net increas dilut increas barclay life scienc tool diagnost
laboratori corp america hldg lh
overweight labcorp remark track
record execut led lead organ
growth augment value-enhanc
acquisit covanc acquisit continu
theme expect expertis
organ posit labcorp premier
partner choic companion diagnost play
greater role clinic decis make
labcorp integr strategi covanc yield
higher sustain growth profil compani
addit lab industri consolid lead
acceelr revenu ep growth upsid
case reflect upsid ep
reimburs headwind congression
action oner clinic lab
hospit begin greater penetr esoter test
volum downsid case reflect
downsid ebitda billion
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
biggest area focu us mettler toledo growth compani
industri segment includ core industri product inspect mettler
toledo notabl underperform date ytd vs
think mostli relat recent moder organ growth compani
well weaker gross margin trend partial due tough comp
slower organ growth mostli driven moder compani
industri segment rev driven tougher comp normal
capit sale sale lab segment sale good structur tailwind
back healthi end market fund final compani food retail
segment sale add quarterli volatil near term comp reason
price continu import lever organ growth
margin expans compani guidanc assum million repurchas
year though capit deploy could drive upsid reiter equal weight
estestestestestestest thousand except per share year end dec growth growth growth servic growth growth growth organ growth ex-fx growth product revenu product revenu inc servic gross margin inc y/i y/i ex-fx growth growth y/i growth growth y/i stock base sg growth ebitda growth angibl oper incom ebit ebit margin ex growth y/i expens debt charg incom pre-tax growth tax net net growth dilut adj basic dilut growth net basic dilut barclay life scienc tool diagnost
mettler toledo statement
estestestestest thousand except per share year end dec activ net tax tax benefit work capitaltrad account current account work oper growth adj net activ capit growth sale cash use invest activ proce stock option tax financ common paid per cash use financ chang cash equival equival growth adj net barclay life scienc tool diagnost
estestestestest thousand except per share year end dec defer tax expens current plant defer tax non-curr equitiesaccount defer tax term term tax sharehold liabilit barclay life scienc tool diagnost
equal weight market leader
precis weigh analyt instrument
compani dispar custom base allow
differenti unit price time consist free
cash flow deploy toward tuck-in
share repurchas biggest near-term risk
relat valuat share screen rich
opinion
better execut end market perform drive
upsid ebitda forecast re-rat
ev/ebitda multipl gener upsid
case
macro pressur end market perform drive
downsid ebitda forecast
valuat re-rat ev/ebitda multipl
gener downsid case
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
say psych like
get paid critic
 takeaway
 genesight view
american journal psychiatri
 model updat
myriad set revenu ep guidanc upcom earn
investor prepar conserv initi forecast myriad laid
consider confer call discuss acquisit
counsyl hct myriad note expect increment rate pressur next year
though carry-ov coverag
decis counsyl acquisit expect close model
end quarter myriad caution sale territori realign would caus
emb addit conservat guidanc usual though acquisit
expect neutral ep year surpris market look past
announc counsyl move out-of-network
new product myriad assum
reimburs coverag decis beyond alreadi earn remain cautiou
potenti near-term genesight coverag dilig show
commun psych strongli favor test thought academ psych broadli neg
think win academ critic guidelin support payor
coverag reiter equal weight rate note forecast
consensu
myriad trade perform day earn day earn
myriad mix revenu
estestestestestestestincom statement diagnost y/i q/q clinic y/i q/q y/i organ q/q debt y/i gross y/i mdx test mdx mdx revenu pharma clinic pharma/clin gross gross margin expens ex-stock base y/i bad sg base stock sg y/i ebitda y/i incom ebit y/i interest debt interest invest pre-tax y/i tax tax net net y/i averag share basic y/i barclay life scienc tool diagnost
equal weight
crossroad look manag
competit concern hereditari cancer test
drive growth new product view
thesi balanc point
expect revenu acceler new product
launch carri greater increment margin
commerci upsid case
reflect upsid ep
myriad face new competit hereditari
cancer test commerci new product
face rigor review payor downsid
case reflect multipl downsid
ep
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
focus organ growth compani two
segment model organ growth diagnost rev appear
solid foot compani make invest genet vanadi nipt
genet screen acquir novaseq lab though also requir
invest could dilut margin expans model organ growth
discoveri analyt system segment rev lack product asset
caus segment under-perform rel peer continu de-
lever follow euroimmun acquisit net debt ebitda believ
near-term capit deploy unlik summari made
lot progress transform busi past month think long-term
target high-singl digit organ growth oper margin
aspir trade premium tool peer ebitda despit
factor vs peer reiter rel underweight rate
estestestestestestestincom statement growth growth growth growth growth growth growth y/i growth y/i organ adj growth product product revenu inc revenu inc servic servic gross gross margin inc gross margin inc growth growth base ebitda growth acquir oper incom ebit growth invest debt expens pre-tax pre-tax growth incom tax net net growth dilut adjust ep continu opsbas adj adj net barclay life scienc tool diagnost
statement flow
estestestestestestest statement activ net gain loss discontinu charg defer debt financ acquir inventori tax postretir gain disposit work capit account reciev expens work continu disc oper growth net activ capit growth surrend life restrict cash cash use invest discontinu cash use invest activ payment revolv credit facil lt revolv credit facil prepay sale senior debt financ hedg payment credit acquisition-conting tax benefit stock issuanc common per cash use financ discontinu cash use financ chang cash chang cash equival equival growth adj net barclay life scienc tool diagnost
sheet assetscash cash receiv current asset discontinu current plant plant equip secur asset asset asset disc sharehold equityshort-term restructur contract termin expens current liabil discontinu current liabiti discontinu stockhold liab stockhold barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight compel
portfolio nich product across environment
human health long-term outlook
organ growth margin improv
compel believ share
range-bound near term get better
visibl emerg market revenu
opportun china nucleic acid test
newborn screen drive upsid
ebitda forecast upsid ebitda
million yield upsid case
emerg market fx remain pressur drive
downsid estim
downsid ebitda million yield downsid
case
view focu earn health abil sustain industri
lead organ growth despit potenti nois one compani key strateg
partner takeda remind may takeda announc would acquir
shire deal valu roughli billion given health relationship takeda
top custom initi nervous around potenti disrupt
said also see lot potenti opportun around transact health could
grow takeda take addit busi shire result believ
import deliv peer organ growth result
outlook street expect model organ growth
believ support increment contribut strateg partnership strong
recent book activ level growth actual repres conserv
outlook rel recent trend overal continu believ differenti growth
deserv differenti multipl takeda believ deal actual expand
valu strateg relationship long term reiter
pleas see takeda analysi
page
solid growth book
estestestestestincom statement y/i growth organ revenu net revenu revenu inc inc margin gross gross margin inc gross margin inc expens ex-comp sg compens stock comp total sg total sg margin ebitda margin ebitda margin margin expens annual bs debt pre-tax incom incom attribut minor net averag sharesbas ep continu opsbas barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight health lead cro
focus late stage clinic develop
believ approach data util clinic trial
posit well increas demand
biopharma sponsor augment recent
acquisit symphoni health view valuat
attract context health market-
combin better clinic research growth
augment new data capabl drive
upsid ebitda forecast upsid case
repres upsid ebitda
weaker growth matur strateg partnership
could limit upsid organ growth margin
expans downsid case repres
downsid ebitda million
strong stock perform ytd vs though
share still screen attract sever metric think stock benefit
clean result commentari well turn better growth focus
core organ growth underli growth support solid end market condit
compani sampl prep portfolio addit quantiferon continu
number tailwind back follow launch gener test grow
guidelin support opportun compani collabor diasorin
cover also look updat traction generead workflow
well qiastat-dx approach launch custom
capit deploy flexibl deploy capit million
outstand repurchas author could drive upsid remaind
year believ share still screen attract given exposur person
medicin hsd organ growth trajectori recur revenu substanti
runway improv margin long-term reiter overweight rate
pleas see report
estestestestestassumpt growth growth acquir organ organ growth ex-u growth total growth growth total growth growth total growth growth growth growth molecular growth growth molecular growth growth total diagnost growth growth total growth growth total growth growth total test growth growth total barclay life scienc tool diagnost
estestestestestincom statement y/i q/q growth organ growth cog ex-dep cog inc dep gross profit ex-dep gross margin inc dep y/i share-bas sg y/i y/i flow ebitda y/i oper incom ebit y/i invest asset debt outstand incom expens interest pre-tax pre-tax tax operationsnoncontrol loss incom net incom average share average share ep continu increas barclay life scienc tool diagnost
overweight reach inflect
point serv baselin
acceler growth molecular diagnost
look forward leadership companion
diagnost develop next gener
sequenc capabl give us visibl
million near-term revenu opportun
number avenu growth
give investor better visibl revenu growth
upsid case reflect upsid
ep
price competit diagnost pressur
result estim come guidanc
expect downsid case reflect
downsid ep
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas see upgrad report
quest
risk/reward new payor
paradigm upgrad ow
key focu quest earn potenti increment growth
stem lab industri consolid term volum model acceler
growth contribut acquisit addit volum
benefit movement easter/good friday lack sever
weather quarter lab consolid central overweight thesi
watch trend close inflect hospit outsourc recent manag
commentari suggest dialogu potenti target remain activ view
recent paus deal activ function rapid pace deal close
end model adjust ebit growth due impact pama though
increment volum would upsid driver given increment volum
model ep also benefit lower adjust tax rate
final look commentari surround quest new payor contract
begin januari specif interest
detail relat potenti chang lab benefit design chang drive
addit share toward labcorp quest
assumptionstot growth equival test y/i lab organ total requisit y/i y/i organ net new weather calendar underli ppa per y/i y/i organ rev medicar pama overal y/i organ growth clinic dx rev pre- debt lab y/i y/i organ total barclay life scienc tool diagnost
million except per share dataestestestestestincom increas debt debt debt gross lab increas equival organ increas net margin net sg net comp sg net increas intang oper ebitda margin net oper profit ebit margin net interest expens debt share earn joint expens pre-tax pre-tax provis incom tax net net average share average share ep ep increas item ens net incom growth net ep growth incom statement mn
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
upsid case assum quest aggreg
increment test share drive upsid
case ep earn begin
acceler believ multipl room
expans well given long runway
downsid case assum softer util
well increment wage pressur busi
cost repres downsid
case ep
overweight believ quest long
runway deliv strategi acceler growth
deliv oper excel point new
payor relationship help drive lab test share
toward nation lab time addit
believ quest meaning leverag
diagnost data asset custom
focus growth trend quidel cardiac immunoassay test segment
sign revenu synergi would major posit view
sever reason remind posit surpris investor cardiac revenu
beat deliv revenu vs forecast segment
repres newli acquir triage/bnp product aler manag
incentiv salesforc drive cross-sel compani hospit account
sofia rapid immunoassay test obvious strength recent flu season help
drive long tail annuiti sofia though may also help earn share
cardiac test revenu synergi would show acquisit bear
fruit quickli would also drive revenu upsid versu base case model everi
better sale growth would drive upsid overal revenu addit demonstr
success revenu synergi would bode well futur poc deal
hunt rapidli de-leverag year end legaci believ
import updat around recent progress savanna revenu see
season softer sale flu subsid aggress flu season limit
visibl revenu view organ growth forecast ex-flu
conserv reiter overweight rate continu think carri
signific strateg valu point care poc test
pleas see analyst day
review
estestestestestassumpt productssofia total revenu placement pull-through y/i instal growthsavanna instal grant y/i organ barclay life scienc tool diagnost
estestestestestincom statement organ organ growth margin inc comp base comp ebitda invest debt pre-tax tax tax net dilut growth net dilut comp per net net growth barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight lead innov
point care poc test compani
leverag strength rapid infecti diseas
test build broader-bas diagnost platform
excit potenti sofia
penetr low-volum account also provid
compel solut address retail poc market
new product launch allow grow
market infecti diseas test take share
compani abl leverag infrastructur drive
synergi triag acquisit see upsid
share reflect upsid cash ep
risk pertain new molecular entrant
potenti take market share
infecti diseas test see downsid share
reflect downsid cash ep
believ focu book clinic segment syneo
recent lag behind peer follow merger inc research
inventiv health believ nervous around potenti impact
deal compani abil win busi nervous support
net book-to-bil meaning lag peer shown
chart syneo show improv book toward peer group
believ would posit sentiment said believ share partial
embed favor updat earn recent confer commentari
support increas share compar sinc
earn may given recent run share remain cautiou around
near-term setup earn reiter equal weight rate
note averag includ lh iclr
estestestestestincom statement growth growth growth y/i growth net revenu adj revenu inc revenu inc gross gross margin inc gross margin inc gener growth adj ebitda growth ebitda growth net net ebit margin ebit invest debt pre-tax pre-tax growth incom tax net net growth growth share share net basic dilut net incom dilut barclay life scienc tool diagnost
equal weight inc research inventiv
third largest cro largest provid commerci
solut merger creat opportun
complement offer two organ
drive revenu synergi said cautiou
around pro-forma leverag ttm ebitda
recent weak commerci solut
combin better commerci solut
segment growth cross-sel synergi drive
upsid ebitda forecast upsid case
repres upsid ebitda
oper execut merger integr
pressur new busi award earn growth
commerci solut segment
prolong weak downsid case
repres downsid ebitda million
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas also see
custom
think thermo fisher favor setup head earn
biopharma end market growth repres notabl area upsid potenti
compani remind thermo fisher essenti maintain organ growth forecast
remaind earn despit momentum across busi
overal organ growth best amongst life scienc tool peer follow
robust growth biopharma end market condit alpha driver
growth also featur upsid recent patheon
acquisit reassur see recent deal perform well given
overal strength end market activ difficult us see recent momentum
moder compani forecast overal organ growth
fx also note thermo fisher conserv peer use
trail fx methodolog rather spot rate think unlik guidanc need
chang relat recent usd strength reiter overweight rate view
valuat attract ep context consist oper
strategi upsid opportun consolid biopharma
workday scienc y/i y/i y/i product y/i y/i store contributionlif scienc store store store store store store product store store store store revenu store store revenu acquisit revenu currenc barclay life scienc tool diagnost
scienc growth particularli strong led growthexcel growthstrong growthmor mutedmodest growthstrong growthstrong growthbiosciencesstrong demandparticularli strong growthstrong growthstrong growthstrong growthnext sequencingstrong growthteen growthl growthexcel growthstrong demandstrong growthet analysi growthstrong demandanalyt appliedcontinu core weaknessindustri soft appli well lsd overallindustri continu weaknessgrew lsd appli strong order industrialgrew compani averag appli safeti channel industrialgrew compani averag appli return growth chemicalmsd growth good china growthmsd growthhsd growthmass spechsd growth growth strong perform strong growthstrong growthstrong growthstrong growthstrong growthchromatographystrong growthhsd growth growth strong perform strong growthstrong growthstrong growthstrong growthstrong growthfei companystrong oper executionexcel oper performancedouble-digit growthstrong growthstrong growthspecialti dx clinic dxsolid growth across segmentsimmuno-dx similar trend good growth immuno transplant dxsimilar trend lsd strength clinic similar trend lsd strength clinic transplant particularli stronglsd growth transplant immunodiagnosticslsd strong season busi clinic transplant dxlsd particularli strong healthcar channellab product govtlsd growthlsd growth grew slightli lsd growthlsd growthlsd growthmsd growth europ chinahsd growthmsd growthpharma biotechhsd growthldd growthhsd growthhsd growthmsd growthmsd growthbiopharma servicesveri strong growth growth littl slower particularli strong strong perform unfavor mix biopharma servicesunfavor mix biopharma servicesunfavor mix biopharma servicesgrow wellstrong growthpatheon barclay life scienc tool diagnost
estestestestestestestincom statement growth growth growth organ adj product product product revenu inc servic servic gross margin inc sg stock comp total sg product margin oper incom margin improv w/ improv annual bs annual bs debt item expens pre-tax tax benefit net averag sharesbas ep continu opsbas adj adj full-year barclay life scienc tool diagnost
thermo fisher statement flow
estestestestestesteststat activitiesnet discontinu dispos discontinu continu defer incom gain sale stock-bas interest expens convert benefit stock-bas comp charg sale non-cash expens work capitalaccount retir chang work cash provid continu cash use discontinu oper growth net activitiesacquisit net cash growth sale available-for-sal sale sale retir note increas restrict deriv invest activ use discontinu invest cash use invest activitiesnet proce issuanc long-term commerci paper convert long-term short-term note per proce issuanc proce issuanc employe benefit stock-compens financ activ cash provid financ rate effect equival equival growth adj net debt ttm barclay life scienc tool diagnost
estestestestestestestbal sheet asset cash receiv less allow tax current current less accumul intang asset payrol employe incom accru current incom long-term convert debt sharehold liabil barclay life scienc tool diagnost
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight thermo fisher market leader
across divers portfolio life scienc tool
diagnost impress global reach across
custom class end market compani
consist track record organ growth capit
deploy manag execut
recommend share core hold exposur
innov healthcar
see upsid thermo fisher target
capit deploy better result
life acquisit upsid case reflect
upsid ebitda billion
thermo fisher exposur econom activ
end market could impact growth
downsid case reflect downsid
ebitda billion
pleas see asm
takeaway
takeaway asm
focus organ growth guidanc earn
cautiou top line miss remind surprisingli miss
organ growth earn organ vs guidanc attribut
mass spectrometri sale well india follow implement gst despit
miss maintain full-year outlook organ growth inher
impli lost sale expect come back point
year mass spec commentari surpris us appear peer may
out-innov water recent product cycl compani
commentari remain cautiou recent investor confer ceo
chri oconnel note core high perform compani
success recent year probabl lost littl bit share
although q-tof world differ trap world term type
applic run despit concern trade premium sever
life scienc tool peer ebitda vs peer
equal weight underweight first think like
come back new product cycl point next year notabl
compani highlight progress bio-tof launch think
addit end market condit biopharma remain strong compani
captiv custom base liquid chromatographi given fda regul drug develop
final track record consist capit return
sharehold expect anoth healthi quarter buy-back model
reiter equal weight rate
custom
focus
water organ growth guidanc call bounc back
miss
revenueorgan growth adj guidanc guidanc interest barclay life scienc tool diagnost
estestestestestestestincom statement growth growth growth growth growth growth y/i growth y/i organ adj growth product product product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth growth y/i administr growth growth y/i base sg stock base oper growth growth y/i ebitda growth acquir intang oper incom ebit growth debt invest pre-tax pre-tax growth benefit incom tax net net growth adj adj net barclay life scienc tool diagnost
water statement flow
estestestestestestest activ net doubt account account incom non-cash work capitalaccount current payabl accru current revenu custom chang work oper growth adj net growth acquisit net cash intellectu properti sale sale cash use invest activ proce debt debt issuanc stock treasuri tax benefit relat stock option debt swap deriv paid per cash use financ exchang rate chang cash cash increas decreas cash cash cash equival begin cash equival end growth adj net barclay life scienc tool diagnost
estestestestestestestbal sheet cash receiv current current plant equip asset payabl employe revenu custom incom current current portion retir incom tax long-term stockhold liab stockhold barclay life scienc tool diagnost
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight admir track
record above-market revenu growth margin
given compani market domin
pharmaceut custom chromatographi
said balanc water success view
difficult gener sustain above-
market earn growth reflect
biopharma remain area strength higher
consum margin drive upsid
ebitda expect upsid ebitda
million yield upsid case
fund biotech pressur capit invest
life scienc tool drive downsid
ebitda estim downsid ebitda
million yield downsid case
valuat methodolog risk
valuat methodolog price target repres ebitda estim billion multipl repres
upper end histor valuat believ warrant combin compani end market acceler growth
risk may imped achiev barclay research valuat price agil exposur econom activ
end market could impact growth addit exposur global economi could impact growth requir activ dilig
cyclic natur agil busi make forecast guidanc rel challeng
valuat methodolog price target repres ebitda estim million
risk may imped achiev barclay research valuat price depend intern
academ end market drive revenu growth compani addit chang foreign exchang rate neg impact
revenu earn growth final compani instrument-bas revenu depend pose risk around capit cycl
valuat methodolog price target base ebitda million
risk may imped achiev barclay research valuat price long replac cycl limit
consum exposur reliant share gain end market perform drive growth busi model
predic end user sale trend toward central purchas would risk food retail busi rel slow
grower manag profit return final cyclic core industri busi sensit advers
valuat methodolog price target repres ebitda estim million
risk may imped achiev barclay research valuat price emerg market exposur greater
peer repres rel growth risk addit emerg market exposur believ could risk custom
purchas product weaker currenc highli depend end market growth drive organ revenu
take decis make manag hand
valuat methodolog price target repres ebitda estim billion
risk may imped achiev barclay research valuat price thermo fisher depend econom
growth end market addit chang foreign exchang rate neg impact revenu earn growth final
compani recent complet acquisit patheon fei compani carri integr risk
valuat methodolog price target repres ebitda estim million
risk may imped achiev barclay research valuat price water depend biopharma
end market drive revenu growth compani addit chang foreign exchang rate neg impact revenu
earn growth final compani instrument-bas revenu depend pose risk around capit cycl
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
